PA Media on MSN5m
New Alzheimer’s drugs should be available on NHS, says sufferer’s wife
New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease. The drug ...
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...
UK regulator approves second Alzheimer's drug in months but government won't pay for it
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...
FOX 13 Seattle on MSN5h
Alzheimer's study in Seattle makes new findings for future therapies
In the heart of Seattle, some of the world’s most brilliant minds study the brain at the Allen Institute, where researchers ...
pharmaphorum46m
Lilly's Alzheimer's drug gets UK nod, but no NHS funding
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...
pharmaphorum1h
Lilly's Alzheimer's drug gets UK nod but won't be NHS-funded
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...
Clinical trials sparking hope for Alzheimer's patients: ‘Holding my own'
A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...
i1h
Second Alzheimer’s ‘wonder drug’ blocked for use on NHS due to high costs
NHS spending watchdog said donanemab, which would have been available to around 70,000 people in England and Wales, "does not ...
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in ...
Alzheimer’s wonder drug faces NHS block over cost
The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...
BioSpace18h
Roche Trims Another Alzheimer’s Prospect, Ending UCB Collabortion
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...